A robust evaluation of the continuous dopaminergic stimulation hypothesis may require a longer acting levodopa preparation. In fluctuating Parkinson's disease (PD) patients, treatment of PD using ...

Professor Karlo Malaga leads research focusing on pinpointing specific areas in the subthalamic region where deep brain ...

Treatment of Parkinson's disease is in large part based on the administration of levodopa. The use of this drug is limited by ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Levodopa (top right ... These findings are of importance to Parkinson's patients, who often experience gastrointestinal problems such as constipation, and show the potential side effects of ...

From family members, to friends, to beloved members of society, Parkinson’s disease impacts more than 10 million people ...

Further information Decision makers have concluded that the clear rationale to not evaluate this product is due to it being a change to the formulation of an existing product as per section 7.1.3 of ...

MSA is divided into MSA-C (cerebellar type) which has more symptoms of ataxia (incoordination) and MSA-P (parkinsonian type) which has more parkinsonian symptoms but is relatively unresponsive to the ...

The dopamine precursor levodopa is central to treatment for Parkinson's disease, but causes dyskinetic involuntary movements in many patients. Investigations carried out in Canada show that ...

That means Duopa is usually reserved for use in people with advanced Parkinson's disease who are still responding well to levodopa-based therapy. However, despite its limitations, the product ...

A new study led by a Bucknell biomedical engineering professor has identified key insights into optimizing deep brain stimulation for Parkinson’s disease patients to help alleviate symptoms such as ...